ABSTRACT
Objective To investigate the intervention effects of Jiawei Ditan Decoction on oxidative stress and inflammatory reaction in elderly patients with obstructive sleep apnea hypopnea syndrome (OSAHS).Methods A total of 60 OSAHS patients with deficiency of phlegm and blood stasis mutual junction were enrolled,and randomly divided into treatment group (n=30,receiving JiaweiDitan Decoction+ conventional treatment for 12 weeks) and control group (n=30,receiving conventional treatment for 12 weeks).The clinical symptoms integral,Epworth Sleepiness Scale (ESS),apnea hypopnea index (AHI),minimum oxygen saturation (SaO2),superoxide dismutase (SOD),malondialdehyde (MDA),tumor necrosis factor (TNF)-α interleukin (IL)-6,and C-reactive protein (CRP) were observed before and after treatment.Results The clinical symptoms integral,AHI value,minimum SaO2,ESS score,levels of SOD,MDA,TNF-α,IL-6 and CRP were significantly improved in treatment group after treatment as compared with pretreatment [(11.65 ± 3.82) points vs.(14.32±4.25) points,(21.18 ± 12.37) times/h vs.(29.16 ± 13.58) times/h,(83.24±7.42)％ vs.(76.92±11.91)％,(7.12±4.84)points vs.(10.01±4.16) points,(99.24± 13.15)×103 U/L vs.(87.511±14.82) ×103 U/L,(8.56 ± 3.23) μmol/L vs.(11.25±3.41) μmol/L,(50.63±10.57) ng/L vs.(58.92±11.65) ng/L,(78.12±15.92) ng/L vs.(89.13± 16.54) ng/L,(9.93±5.25) mg/L vs.(13.59±4.92) mg/L,t=2.559,2.379,2.467,2.480,3.243,3.137,2.887,2.651,2.786,respectively,all P＜0.05].All the above indicators after treatment had significant differences between the treatment group and the control group [(11.65 ± 3.82) points vs.(13.89±4.45) points,(21.18± 12.37) times/h vs.(28.03± 13.12) times/h,(83.24±7.42)％ vs.(78.26±10.15)％,(7.12±4.84) points vs.(9.56±7.12) points,(99.24± 13.15)×103 U/Lvs.(90.13±13.56)×103 U/L,(8.56±3.23) μmol/L vs.(10.86±3.65)μmol/ L,(50.63±10.57) ng/L vs.(56.52±11.04) ng/L,(78.12±15.92) ng/L vs.(87.81±15.61) ng/ L,(9.93±5.25) mg/L vs.(12.97±5.03) mg/L,t=2.092,2.018,2.169,2.009,2.642,2.585,2.111,2.380,2.290,respectively,all P＜0.05].Conclusions Jiawei Ditan Decoction could improve the clinical symptoms and has the intervention effect on oxidative stress and inflammatory reaction in elderly patients with OSAHS,which provides the experimental basis for the treatment of senile OSASH with Chinese herbal medicine.
ABSTRACT
Objective To analyze and compare efficacy and safety of different chemotherapy regimens in the treatment of elderly patients with advanced gastric cancer. Methods 60 elderly patients admitted to our hospital with advanced gastric cancer were selected as research subjects , and divided into experimental group and control group depending on the treatment of chemotherapy. The experimental group were treated with Gio oxaliplatin (SOX), and patients in the control group accepted Olivier Elizabeth, leucovorin and fluorouracil (FOLFOX6) treatment. Compare and analyze the efficacy of the two groups after two cycles of therapy. Results By chemotherapy, recent efficiency and disease control rate were not significantly different (P>0.05) between the two groups;and there was also no significant difference in the incidence of adverse reactions,such as adverse reactions, fatigue weakness, gastrointestinal reactions, hand-foot syndrome, oral mucositis (P > 0.05). Conclusion The efficacy was equivalent between FOLFOX6 chemotherapy SOX test group and the control group in the treatment of elderly patients with advanced gastric , and there was no significant difference in the incidence of adverse reactions.
ABSTRACT
<p><b>BACKGROUND</b>Chemotherapy is a main method for patients with advanced non-small cell lung cancer (NSCLC). NSCLC is usually a drug-resistant neoplasm. Innate or acquired drug-resis-tance contributes to the chief cause for bad effect in the treatment of patients with NSCLC. To search for a new anti-cancer drug becomes a goal of clinical oncologists. The aim of the present study is to evaluate the curative effect and side reactions of IRESSA in the treatment of patients with advanced refractory NSCLC.</p><p><b>METHODS</b>The curative investigation was carried out after 100-day oral IRESSA by a dosage of 250mg/d in patients with advanced refractory NSCLC. The patients had ever experienced at least one regimen of chemotherapy.</p><p><b>RESULTS</b>Totally 33 patients enrolled in this study and all were stage IV. There were 25 males and 8 females. All enrolled patients except one patient who died of severe adverse side reaction completed treatment by IRESSA. Thirty-two cases were evaluated. Complete response was obtained in 1 patient (3.1%). Partial response was seen in 11 patients (34.4%). The overall effective rate was 37.5% (12/32). The disease-control rate was 65.6% (21/32). Time to progression was 5.7 months. Overall survival time was 3.3 to 25.9 months (median survival time was 9.6 months). One-year survival rate was 28.1% (9/32). Two-year survival rate was 6.3% (2/32). The longest survivor lived for 25.9 months. The curative effect was correlated with the pathological type, in sequence of alveolar cell carcinoma, adenocarcinoma and squamous cell carcinoma. Almost all the adverse reactions were acceptable. The main adverse reactions included rash, itching of skin, arthralgia, diarrhea, anorexia, nausea, vomiting, dizziness, headache, chest distress and abdominal pain. No patients showed abnormal in liver or kidney function. No electrocardiogram abnormality was found. One patient who had chronic pulmonary fibrosis before died of respiratory failure due to severe interstitial pneumonia.</p><p><b>CONCLUSIONS</b>IRESSA takes better effect on the advanced drug-resistant patients with NSCLC. So IRESSA may be accepted as third line in the treatment of advanced NSCLC and as first line in the treatment of patients with bad constitution who have no opportinities for operation, irradiation therapy or chemotherapy.</p>
